In 2012, government announced that it would launch a pharmaceutical manufacturer whose sole aim of building active pharmaceutical ingredients manufacturing capacity in the country.

Given COVID-19, these shortages of APIs has highlighted deep vulnerabilities in South Africa’s medicine supply chain. Almost all APIs used in the production of medicine in the country are imported, with the vast majority coming from China and India.

This begs the question: What happened to Ketlaphela?

Guest:Prof David Walwyn - Graduate School of Technology Management, University of Pretoria | Director of Reseva (consultancy firm)